EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024
Original story: https://www.benzinga.com/general/biotech/23/03/31160136/eyepoint-pharma-posts-deeper-losses-for-q4-expects-cash-runway-into-2024 by Vandana Singh, Benzinga Editor March 2, 2023 7:01 AM
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!